| Title |
Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial
|
|---|---|
| Published in |
Diabetologia, September 2016
|
| DOI | 10.1007/s00125-016-4083-4 |
| Pubmed ID | |
| Authors |
Christian Ott, Iris Kistner, Mirjam Keller, Stefanie Friedrich, Carsten Willam, Peter Bramlage, Roland E. Schmieder |
| Abstract |
Endothelial dysfunction predicts cardiovascular damage and renal involvement. Animal experiments and human studies indicate an increased nitric oxide (NO) activity and endothelial NO synthase (NOS) expression in the early stage of type 2 diabetes. The aim of the study was to assess the effect of linagliptin on the endothelial function of the renal vasculature. In this randomised, double-blind, parallel-group, investigator-initiated trial, 62 patients with type 2 diabetes were randomly assigned (by computer-generated random code) to receive linagliptin 5 mg (n = 30) or placebo (n = 32) for 4 weeks. The primary objective was to assess endothelial function of the renal vasculature, by constant-infusion input-clearance and urinary albumin/creatinine ratio (UACR), both before and after blockade of NOS with N (G)-monomethyl-L-arginine (L-NMMA). Treatment with linagliptin for 4 weeks reduced fasting, postprandial blood glucose and HbA1c, although not significantly; no change occurred with placebo. Renal plasma flow (RPF) did not change after linagliptin or placebo. After 4 weeks the absolute change in RPF due to L-NMMA was smaller in the linagliptin group than in the placebo group (-46.8 ± 34 vs -65.1 ± 36 ml/min, p = 0.045), indicating a lower basal NO activity after treatment with linagliptin. Consistently, the response of UACR to L-NMMA increased in the placebo group (p = 0.059) but not in the linagliptin group (p = 0.276), pointing to an upregulation of NO activity in the placebo group. No clinically meaningful safety concerns were evident. Our data suggest that treatment with the dipeptidyl peptidase-4 inhibitor linagliptin for 4 weeks prevented the impairment of renal endothelial function due to hyperglycaemia in type 2 diabetes. ClinicalTrials.gov NCT01835678 FUNDING: : This study was funded by Boehringer Ingelheim. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 17% |
| Canada | 1 | 17% |
| Unknown | 4 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 67% |
| Scientists | 1 | 17% |
| Practitioners (doctors, other healthcare professionals) | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Unknown | 49 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 5 | 10% |
| Student > Ph. D. Student | 4 | 8% |
| Other | 4 | 8% |
| Student > Master | 4 | 8% |
| Researcher | 3 | 6% |
| Other | 9 | 18% |
| Unknown | 21 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 38% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 8% |
| Nursing and Health Professions | 2 | 4% |
| Environmental Science | 1 | 2% |
| Biochemistry, Genetics and Molecular Biology | 1 | 2% |
| Other | 2 | 4% |
| Unknown | 21 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 November 2016.
All research outputs
#7,156,855
of 22,899,952 outputs
Outputs from Diabetologia
#2,765
of 5,040 outputs
Outputs of similar age
#111,995
of 337,434 outputs
Outputs of similar age from Diabetologia
#49
of 75 outputs
Altmetric has tracked 22,899,952 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 5,040 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 22.7. This one is in the 45th percentile – i.e., 45% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 337,434 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 75 others from the same source and published within six weeks on either side of this one. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.